摘要
目的:探讨慢性髓系白血病(慢性期)个体化治疗方案的选择。方法:对1例尼洛替尼不耐受的慢性髓系白血病(慢性期)患者的临床资料及治疗过程进行分析。结果:患者在完善相关检查确诊为慢性髓系白血病(慢性期)后给予尼洛替尼治疗。治疗3个月时评估病情,患者虽然获得了主要分子学缓解(MMR)和完全细胞遗传学缓解(CCy R),但在治疗的过程中发生3-4级的肝毒性,经过药物的减量及对症治疗,患者在3次停药后换用伊马替尼治疗,7个月时评估病情达MMR及CCy R。目前患者无任何不良反应,耐受良好。结论:伊马替尼可作为慢性髓系白血病(慢性期)患者对第二代TKI治疗不耐受时的一种治疗方法,其不良事件发生率低且疗效确切。
Objective ：To explore the individualized treatment for patient with chronic phase chronic myeloid leukemia （CML -CP）. Methods：The clinical data and treatment process of one CML -CP patient which intolerated to nilotinib were analyzed. Results： Nilotinib was given to the patient once the diagnosis of CML - CP was set. Although major molecular remission （MMR） and complete cytogenetic remission （CCyR） were obtained during treatment for 3 months, a grade 3 -4 hepatotoxicity appeared in the course of treatment. With drug reduction and symptomatic treatment, nilotinib was discontinued after 3 withdrawals and replaced with imatinib in January 11, 2015. The patients achieved MMR and CCyR at 7 months after imatinib replacement. At present, the patient tolerated well without any adverse events. Conclusion： Imatinib can be used as a second -line treatment drug for CML patients who was intolerant to nilotinib, and with less adverts, good effect and so on.
作者
齐晶
徐又海
何合胜
QI Jing ,XU You-Hai ,HE He-Sheng(Department of Hematology, Yijishan Hospital, Wannan Medical College, Wuhu 241001 ,Anhui Province, Chin)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2018年第2期407-411,共5页
Journal of Experimental Hematology
